Integrated Filing — IndAS



General information about company

Scrip Code 543960
NSE Symbol CONCORDBIO
MSEI Symbol NA
ISIN INE338H01029
Name of company Concord Biotech Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 13-11-2025   16:30:00
End date and time of board meeting 13-11-2025   18:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 24,705.75 45,104.51
Other income 1,335.21 2,702.97
Total income 26,040.96 47,807.48
2 Expenses
(a) Cost of materials consumed 5,730.43 11,721.41
(b) Purchases of stock-in-trade 1,364.51 2,649.14
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,193.31) (4,958.41)
(d) Employee benefit expense 4,445.55 8,235.29
(e) Finance costs 5.91 11.77
(f) Depreciation, depletion and amortisation expense 1,839.15 3,616.78
(f) Other Expenses
1 Power and Fuel 2,852.80 5,800.30
2 Other Expenses 3,656.66 6,667.98
Total other expenses 6,509.46 12,468.28
Total expenses 17,701.70 33,744.26
3 Total profit before exceptional items and tax 8,339.26 14,063.22
4 Exceptional items 0.00 0.00
5 Total profit before tax 8,339.26 14,063.22
6 Tax expense
7 Current tax 2,199.60 3,607.45
8 Deferred tax 62.52 122.07
9 Total tax expenses 2,262.12 3,729.52
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,077.14 10,333.70
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 229.14 378.37
16 Total profit (loss) for period 6,306.28 10,712.07
17 Other comprehensive income net of taxes 2,185.18 1,903.30
18 Total Comprehensive Income for the period 8,491.46 12,615.37
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 6,358.09 10,763.88
Total profit or loss, attributable to non-controlling interests (51.81) (51.81)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 2,186.55 1,904.67
Total comprehensive income for the period attributable to owners of parent non-controlling interests (1.37) 1.37
21 Details of equity share capital
Paid-up equity share capital 1,046.16 1,046.16
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 6.03 10.24
Diluted earnings (loss) per share from continuing operations 6.03 10.24
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 6.03 10.24
Diluted earnings (loss) per share from continuing and discontinued operations 6.03 10.24
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the statement of unaudited consolidated financial results for the quarter and six months ended September 30 2025 1 The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 13 2025 The Statutory Auditors of the company have carried out a limited review of the said results 2 The consolidated financial results of the Group include information of wholly owned subsidiary Concord Lifegen Limited wef 21st July 2025 subsidiary Stellon Biotech Inc wef 1st July 2025 and joint venture Concord Biotech Japan KK 3. The Group is engaged in the business of manufacturing and trading in pharmaceutical products The entire business is considered as a single operating segment in terms of Indian Accounting Standard Ind AS 108 Operating Segment 4. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 read together with Companies Indian Accounting Standards Rules 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 78,668.85
Capital work-in-progress 7,417.28
Investment property 0.00
Goodwill 39.63
Other intangible assets 182.86
Intangible assets under development 116.04
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 452.01
Non-current financial assets
Non-current investments 4,055.71
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 524.99
Total non-current financial assets 4,580.70
Deferred tax assets (net) 1,789.94
Other non-current assets 1,090.41
Total non-current assets 94,337.72
2 Current assets
Inventories 27,627.73
Current financial asset
Current investments 31,231.76
Trade receivables, current 39,678.89
Cash and cash equivalents 1,728.80
Bank balance other than cash and cash equivalents 175.38
Loans, current 0.00
Other current financial assets 5,003.36
Total current financial assets 77,818.19
Current tax assets (net) 0.00
Other current assets 2,538.22
Total current assets 1,07,984.14
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,02,321.86
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,046.16
Other equity 1,81,700.06
Total equity attributable to owners of parent 1,82,746.22
Non controlling interest (65.18)
Total equity 1,82,681.04
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 56.51
Total non-current financial liabilities 56.51
Provisions, non-current 245.80
Deferred tax liabilities (net) 3,840.30
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 4,142.61
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,135.99
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 7,522.49
Total Trade payable 8,658.48
Other current financial liabilities 4,433.20
Total current financial liabilities 13,091.68
Other current liabilities 1,805.60
Provisions, current 556.95
Current tax liabilities (Net) 43.98
Deferred government grants, Current 0.00
Total current liabilities 15,498.21
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 19,640.82
Total equity and liabilites 2,02,321.86
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain/ (loss) on defined benefit plans 202000 -3005000
2 Income tax relating to re-measurement gain/ (loss) on defined benefit plans -51000 756000
3 Fair value changes on equity investments through OCI 259815000 225354000
4 Income tax relating to fair value changes on equity investments through OCI -40899000 -32226000
Total Amount of items that will not be reclassified to profit and loss 2,190.67 1,908.79
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Foreign currency translation reserves -549000 -549000
Total Amount of items that will be reclassified to profit and loss (5.49) (5.49)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 2,185.18 1,903.30



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 14,063.22
Adjustments for reconcile profit (loss)
Adjustments for finance costs 11.77
Adjustments for decrease (increase) in inventories (3,661.01)
Adjustments for decrease (increase) in trade receivables, current 13,079.04
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (997.42)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (967.66)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (2,522.03)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 757.42
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 3,616.78
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 148.02
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (690.11)
Adjustments for dividend income 0.00
Adjustments for interest income 132.22
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (238.01)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (989.75)
Other adjustments to reconcile profit (loss) (1.30)
Other adjustments for non-cash items (179.84)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 7,233.68
Net cash flows from (used in) operations 21,296.90
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 6,188.43
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 15,108.47
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 47,780.47
Other cash payments to acquire equity or debt instruments of other entities 46,133.26
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 10.65
Purchase of property, plant and equipment 5,349.93
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 1,431.40
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 132.22
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (2,128.45)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 38.11
Payments of lease liabilities 109.88
Dividends paid 11,193.67
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (11,341.66)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1,638.36
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 1,638.36
Cash and cash equivalents cash flow statement at beginning of period 90.45
Cash and cash equivalents cash flow statement at end of period 1,728.81





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R & Co. LLP Yes 31-07-2028